OncoMatch/Clinical Trials/NCT07215182
[68Ga]Ga-FAPI Total Body PET/CT for Better and Faster Imaging in Cancer
Is NCT07215182 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies [68Ga]Ga-FAPI-46 for malignant melanoma stage iv.
Treatment: [68Ga]Ga-FAPI-46 — The goal of this clinical trial is to investigate the use of the tracer \[68Ga\]Ga-FAPI-46 for PET/CT-imaging in response evaluation of patients with advanced stage malignant melanoma treated with immune checkpoint inhibitor therapy (ICT). The main question it aims to answer is: • Can \[68Ga\]Ga-FAPI-46 PET/CT improve response evaluation in patients suffering from advanced stage malignant melanoma treated with ICT and potentially serve as a biomarker. Researchers will compare findings on the experimental \[68Ga\]Ga-FAPI-46 PET/CT with findings on standard imaging (\[18F\]FDG PET/CT). Participants will undergo: * Two \[68Ga\]Ga-FAPI-46 PET/CT scans: one before treatment initiation with ICT and one after three months. * Two blood samples * Passive follow-up 6 months after the last scan \[68Ga\]Ga-FAPI-46 PET/CT
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Melanoma
Disease stage
Required: Stage IV
Metastatic disease required
Histological verified metastatic or locally advanced malignant melanoma
Prior therapy
Cannot have received: immune checkpoint inhibitor
Previous systemic oncological treatment with ICT
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07215182 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior immune checkpoint inhibitor disqualifies patients from enrollment.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages